CareLit Fachartikel

Pooled analysis of data from the TOMORROW and INPULSIS® trials of nintedanib in IPF

C Neurohr, L Richeldi, V Cottin, M Selman, T Kimura, S Stowasser, KK Brown · Pneumologie · 2016 · Heft 02

Dokument
1084850
CareLit-ID
Jahr
2016
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Pneumologie
Autor:innen
C Neurohr, L Richeldi, V Cottin, M Selman, T Kimura, S Stowasser, KK Brown
Ausgabe
Heft 02 / 2016
Seiten
–
Erschienen: 2016-02-09 00:00:00
ISSN
0934-8387
DOI
10.1055/s-0036-1571996

Zusammenfassung

Background: The 52-week, Phase II TOMORROW trial and two replicate 52-week, Phase III INPULSIS® trials investigated the efficacy and safety of nintedanib 150 mg twice daily (bid) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). Aim: A pooled analysis of data from the TOMORROW and INPULSIS® trials was conducted to obtain a more precise estimate of the treatment effect of nintedanib. Methods: Results for annual rate of decline in forced vital capacity (FVC), time to first investigator-reported acute exacerbation, change from baseline in St George's Respiratory Questionnaire (SGRQ) total score a…

Schlagworte

Nintedanib Trials Inpulsis Tomorrow Placebo Pooled Patients Baseline Overall Analysis 52-Week Phase Pneumologie